import markdown

# 示例 Markdown 文本
markdown_text = """
## PLX7486: A Dual Kinase Inhibitor in Academic Oncology Research

PLX7486, also identified as chembl3545381, is a small molecule inhibitor under investigation for its therapeutic potential, particularly within oncology. It represents a class of agents designed to target specific pathways crucial for cancer cell proliferation and survival.[[1](https://www.google.com/url?sa=E&amp;q=https%3A%2F%2Fvertexaisearch.cloud.google.com%2Fgrounding-api-redirect%2FAUZIYQHA-RMgkRXqfAHui6SSZ4ChOQhwysqPn4eM7pPgw44hyLApUEwtbp4hVAEiFnpQCXhC7-8iQ08IviAY6Qqy74QIZFH1npEePMFGnfCt-5EpXU3MSIaq_qw7xbIbGY2jOavP4vBAaS8wpzlErLNQ1bgxOvbXptnVUk922P0YU_uw_iGk4ejn8ApXsY_Oyw%3D%3D)]

### 1.1. Overview and Academic Significance of Dual Kinase Inhibition

Dual kinase inhibition involves the simultaneous targeting of multiple protein kinases, which are enzymes critical for cell signaling pathways, including those involved in growth, differentiation, and metabolism.[[2](https://www.google.com/url?sa=E&amp;q=https%3A%2F%2Fvertexaisearch.cloud.google.com%2Fgrounding-api-redirect%2FAUZIYQEZ52vGTngn2glF2Ah7TxunR1dzTfpU7jn9vGNYfR2CnvtNbtkT8Mrl4iCp2iZyQPb3FePnZSXbiQIjuqeSnxCI5yg_ED_C-4-Nix_vJAQVl5ovtAioPk8dbKN5tQD6Z7lQyebmIDIYEXa4MPk%3D)][[3](https://www.google.com/url?sa=E&amp;q=https%3A%2F%2Fvertexaisearch.cloud.google.com%2Fgrounding-api-redirect%2FAUZIYQErNeWHpALMOXP4KzviytA7OoQmfUgS0-M72WSyEwMkOTHpAfa4l4ygHFoOIrpMcPp7wbWznBI-E5LgUZ22KACX93nO2cBmAfis51EULLhzrVOiE8-Dh9fp34LwIZ61A3gjb-I1eS5MTvaS8YNj-eFT3rUoTDLhqA2DKRa6PA%3D%3D)] PLX7486 is characterized as a selective dual inhibitor of two key receptor tyrosine kinases: Colony-stimulating factor-1 receptor (CSF1R), also known as Fms, and the neurotrophic tyrosine kinase receptor types 1, 2, and 3 (TrkA, TrkB, and TrkC, collectively referred to as Trk).[[4](https://www.google.com/url?sa=E&amp;q=https%3A%2F%2Fvertexaisearch.cloud.google.com%2Fgrounding-api-redirect%2FAUZIYQFRrrqqQd9I6dY-upTA9D79pcUEP1jpXIUlpUfBJXqIG1DUqtLwnVeoDT6qj8N93TFcuBbJq_wnAMipDSQmWCC68owYzgdXhViIRijTDlkPknSsqSTqeEVLTjS8k_-Ii9qcgtl897pa2-NlATov5KNhRGmnwmReDDbbYkVpoOt3r1nB6H-IQQ%3D%3D)]

The academic significance of this dual inhibition strategy stems from the multifaceted roles these kinases play in cancer biology:

*   **CSF1R (Fms) and the Tumor Microenvironment:** CSF1R signaling is implicated in the recruitment and proliferation of immunosuppressive myeloid cells, specifically M2-macrophages and myeloid-derived suppressor cells (MDSCs), within the tumor microenvironment. Tumor-associated macrophages (TAMs), often polarized to an M2-like phenotype in advanced tumors, are abundant immune cells in the tumor microenvironment and significantly contribute to tumor progression, angiogenesis, and immunosuppression. Inhibiting CSF1R aims to block the recruitment of these immunosuppressive macrophages, thereby potentially altering the tumor microenvironment to be less conducive to tumor growth and more responsive to anti-tumor immune responses.

*   **Trk Kinases (TrkA, TrkB, TrkC) and Cancer Cell Biology:** Trk proteins are receptor tyrosine kinases that, when overexpressed or mutated, can drive tumor cell proliferation and survival.[[4](https://www.google.com/url?sa=E&amp;q=https%3A%2F%2Fvertexaisearch.cloud.google.com%2Fgrounding-api-redirect%2FAUZIYQFRrrqqQd9I6dY-upTA9D79pcUEP1jpXIUlpUfBJXqIG1DUqtLwnVeoDT6qj8N93TFcuBbJq_wnAMipDSQmWCC68owYzgdXhViIRijTDlkPknSsqSTqeEVLTjS8k_-Ii9qcgtl897pa2-NlATov5KNhRGmnwmReDDbbYkVpoOt3r1nB6H-IQQ%3D%3D)] They mediate signal transduction pathways such as PI3K, RAS/MAPK/ERK, and PLC-gamma. Notably, NTRK gene fusions, which involve these kinases, are recognized oncogenic events in various cancer types. Trk kinases are also believed to facilitate nerve invasion, a process observed in a high percentage of pancreatic ductal adenocarcinoma (PDAC) cases and associated with tumor spread and severe pain.

The academic interest in PLX7486 lies in its potential to exert a comprehensive anti-tumor effect by simultaneously targeting cancer cells directly via Trk inhibition and modulating the immunosuppressive tumor microenvironment via CSF1R inhibition. This dual mechanism is hypothesized to synergize with other anti-cancer therapies, including immunotherapies, by inhibiting the recruitment of immunosuppressive macrophages.

### 1.2. Classification and General Research Focus within Oncology

PLX7486 is classified as an orally available, potent, and selective small molecule kinase inhibitor. It holds the distinction of being a first-in-class dual Trk/Fms inhibitor, falling within the broader category of protein kinase inhibitors, which are a significant class of antineoplastic agents.[[2](https://www.google.com/url?sa=E&amp;q=https%3A%2F%2Fvertexaisearch.cloud.google.com%2Fgrounding-api-redirect%2FAUZIYQEZ52vGTngn2glF2Ah7TxunR1dzTfpU7jn9vGNYfR2CnvtNbtkT8Mrl4iCp2iZyQPb3FePnZSXbiQIjuqeSnxCI5yg_ED_C-4-Nix_vJAQVl5ovtAioPk8dbKN5tQD6Z7lQyebmIDIYEXa4MPk%3D)][[3](https://www.google.com/url?sa=E&amp;q=https%3A%2F%2Fvertexaisearch.cloud.google.com%2Fgrounding-api-redirect%2FAUZIYQErNeWHpALMOXP4KzviytA7OoQmfUgS0-M72WSyEwMkOTHpAfa4l4ygHFoOIrpMcPp7wbWznBI-E5LgUZ22KACX93nO2cBmAfis51EULLhzrVOiE8-Dh9fp34LwIZ61A3gjb-I1eS5MTvaS8YNj-eFT3rUoTDLhqA2DKRa6PA%3D%3D)]

Academic research on PLX7486 has encompassed both preclinical and clinical investigations, primarily focusing on its application in oncology.

**Detailed Research Findings:**

*   **Preclinical Studies:** *In vitro* studies have demonstrated that PLX7486 exhibits direct cytotoxic effects on various murine cancer cell lines, including MC38, SA1N, MB49, 4T1, B16F10, and 3LL, with half-maximal inhibitory concentration (IC50) values generally ranging from 5 to 8 µM over 72 hours. Furthermore, PLX7486 has shown cytotoxic effects on bone marrow-derived macrophages and the murine macrophage cell line RAW264.7, with IC50 values below 1 µM. These studies also indicated that PLX7486 inhibits downstream signaling pathways, including AKT and MAPK.

    **Table 1: *In Vitro* Cytotoxic Effects of PLX7486**

    | Cell Type                     | IC50 (µM) | Time Point (hours) | Observed Effect                                  | Citation |
    | :---------------------------- | :-------- | :----------------- | :----------------------------------------------- | :------- |
    | Murine Cancer Cell Lines      | 5-8       | 72                 | Direct cytotoxic effect                          |     |
    | Bone Marrow-Derived Macrophages | &lt;1        | Not specified      | Direct cytotoxic effect, inhibition of MAPK pathway |     
    | Murine Macrophage Cell Line RAW264.7 | &lt;1        | Not specified      | Direct cytotoxic effect, inhibition of MAPK pathway |     

*   **Clinical Research Focus:** PLX7486 has been evaluated in Phase 1 and Phase 1b/IIa clinical trials for patients with advanced solid tumors. A significant area of focus has been its investigation in pancreatic ductal adenocarcinoma (PDAC), particularly in combination with the chemotherapy drug gemcitabine. The rationale behind this combination therapy is to target nerve invasion, a pathological feature prevalent in over 80% of PDAC cases, which contributes to tumor spread and severe pain. Preclinical models have shown that this drug combination can suppress cancer cell growth and multiplication, with the hope that this will translate into clinical benefits such as improved progression-free survival and pain reduction for pancreatic cancer patients. Research also explores its potential in cancers characterized by activating Trk (NTRK) mutations or NTRK gene fusion mutations, as well as tenosynovial giant cell tumors.

    **Table 2: Kinases Targeted by PLX7486 and Their Roles in Cancer**

    | Kinase Target | Associated Receptor | Role in Cancer                                                                                                                                              **Compound Name** | **PubChem CID** |
| :---------------- | :-------------------- |
| PLX7486         | Not publicly disclosed |
| Gemcitabine       | 60750                 |
"""

# 转换为 HTML
html_output = markdown.markdown(markdown_text, extensions=['tables'])

# 保存为 HTML 文件
with open("output.html", "w", encoding="utf-8") as f:
    f.write(html_output)

print("转换完成！HTML 文件保存在 output.html")